| Literature DB >> 31835526 |
Thangavelu Muthukumar1, Jeong Eun Song1, Gilson Khang1.
Abstract
Over the past few decades, gellan gum (GG) has attracted substantial research interest in several fields including biomedical and clinical applications. The GG has highly versatile properties like easy bio-fabrication, tunable mechanical, cell adhesion, biocompatibility, biodegradability, drug delivery, and is easy to functionalize. These properties have put forth GG as a promising material in tissue engineering and regenerative medicine fields. Nevertheless, GG alone has poor mechanical strength, stability, and a high gelling temperature in physiological conditions. However, GG physiochemical properties can be enhanced by blending them with other polymers like chitosan, agar, sodium alginate, starch, cellulose, pullulan, polyvinyl chloride, xanthan gum, and other nanomaterials, like gold, silver, or composites. In this review article, we discuss the comprehensive overview and different strategies for the preparation of GG based biomaterial, hydrogels, and scaffolds for drug delivery, wound healing, antimicrobial activity, and cell adhesion. In addition, we have given special attention to tissue engineering applications of GG, which can be combined with another natural, synthetic polymers and nanoparticles, and other composites materials. Overall, this review article clearly presents a summary of the recent advances in research studies on GG for different biomedical applications.Entities:
Keywords: cell adhesion; drug delivery; gellan gum; hydrogel; scaffold; tissue engineering
Mesh:
Substances:
Year: 2019 PMID: 31835526 PMCID: PMC6943741 DOI: 10.3390/molecules24244514
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Showing the structure of acylated gellan gum (AGG) and deacylated gellan gum (dAGG).
Figure 2Major routes for preparing gellan gum-based biomaterials [4,32,34,35,36,37,38,39,65,66,67,68,69].
Gellan gum (GG) composites used in the biological fields for various applications.
| Sl No | GG Composites | Applications | Reference |
|---|---|---|---|
| 1 | Xanthan gum (XG) -HAp | Bone tissue engineering | [ |
| 2 | GG-XG-hyaluronan | Bone tissue engineering | [ |
| 3 | GG/Starch | Drug delivery system | [ |
| 4 | GG/alpha amylase | Pharmaceutical and biomedical | [ |
| 5 | GG/PVA-Ofloxacin | Gastroretentive/mucoadhesive drug delivery | [ |
| 6 | GG/kappa-carrageenan | Drugs on the ocular surface | [ |
| 7 | GG/Chitosan | Nasal insert, antifungal agent, coatings, wound healing, antibiotic | [ |
| 8 | GG/kappa-carrageenan/alginates | Antifungal and antimicrobial drugs | [ |
| 9 | GG/XG | Anti-adhesive | [ |
| 10 | GG/pectin | Drug delivery | [ |
| 11 | GG/agar | Biomedical applications | [ |
| 12 | GG methacrylate/gelatin methacrylamide | In scaffolds for load-bearing tissues | [ |
| 13 | GG/alginate | Sustained drug release | [ |
| 14 | GG/titanium dioxide nanoparticles | Wound healing | [ |
| 15 | GG/HAp | Bone, vasculature | [ |
| 16 | GG/Gelatin/genipin | material | [ |
| 17 | GG/PLGA microsphere | Vertebra | [ |
| 18 | GG/Gold nanorods | Bone | [ |
| 19 | GG/Bioglass | Bone | [ |
| 20 | GG/Graphine oxide | Scaffold | [ |
| 21 | GG/HAGG/LAGG blends methacrylation/HA | Intervertebral discs | [ |
| 22 | GG//methacrylation/GG microsphere/gelatin | Load bearing tissue | [ |
| 23 | GG/methacrylation | Intervertebral discs, TE, cartilage repair | [ |
| 24 | GG/Cinnamate | Wound healing | [ |
| 25 | GG/Methacrylated gelatin | Cartilage | [ |
| 26 | GG/HA | Skin repair/vascularization/cartilage regeneration | [ |
| 27 | GG/Laponite beads | Drug release | [ |
| 28 | GG/ gum cordia | Drug delivery | [ |
| 29 | GG/apigenin | Drug release | [ |
| 30 | GG/avidin/boptinylated adhesive | Cell culture | [ |
| 31 | GG/HAp/Lactoferrin | Bone tissue engineering | [ |
| 32 | GG/AuNPs | Anti-cancer drug delivery | [ |
| 33 | GG/AuNPs/DOX | Anti-cancer drug delivery | [ |
| 34 | GG/AgNPs | Antibacterial, cytotoxic | [ |
| 35 | GG/AuNRs | Intercellular drug delivery and imaging | [ |
| 36 | GG/poloxamer 407/carbopol 934P) | Controlled delivery and antibacterial activity | [ |
| 37 | GG/Lactoferrin | Bone Tissue Engineering | [ |
| 38 | GG/insulin | Drug delivery | [ |
| 39 | GG/poly(vinyl) alcohol | Tissue Engineering | [ |
| 40 | GG/levofloxacin hemihydrate | Ophthalmic solution | [ |
| 41 | GG/Polyvinylpyrrolidone (PVP) | Sustained release | [ |
| 42 | Gelatin-grafted-GG-hydrogel microsphere | Cell encapsulation and delivery | [ |
| 43 | GG hydrogel | Cartilage Tissue Engineering | [ |
| 43 | GG/fibrin/agarose | Cartilage regeneration | [ |
| 44 | Ionic crosslinked methacrylated GG/Silk | Meniscus tissue engineering | [ |
| 45 | GG/Polydopamine | Bone tissue engineering | [ |
| 46 | GG/Collagen I, Beta -TCP | Bone graft material | [ |
| 47 | GG-MA hydrogels | Intervertebral Disc | [ |
| 48 | GG/RGD | Cell adhesion, proliferation | [ |
| 49 | GG/ UV crosslinked gelatin-methacryloyl (geMA) | Cartilage grafts bioprinting | [ |
| 50 | GG/acrylamide grafted | Sustained release | [ |
| 51 | GG/ dextran sulfates/ cellulose sulfate | Drug delivery | [ |
| 52 | GG/polyvinylalcoho | Beta-blocker | [ |
| 53 | GG/alginate | Antibiotic, Antinflammatory | [ |
| 54 | GG/polyvinylalcohol | Antibiotic | [ |
| 55 | GG/hyaluronic acid ester/polyvinylalcohol | Wound healing | [ |
| 56 | GG/chitosan/PEG | Wound healing | [ |
| 57 | GG/glucosamine | Oral cancer treatment | [ |
| 58 | GG/ HA | Cartilage regeneration | [ |
| 59 | GG/ poloxamer-heparin | Bone marrow stem cells delivery | [ |
| 60 | GG/PEG | Retinal pigment epithelial cells regeneration | [ |
| 61 | GG/ demineralized bone powder | Bone tissue regeneration | [ |
| 62 | GG/Agar | Cartilage regeneration | [ |
| 63 | GG/Silk fibroin | Chondrogenic differentiation | [ |
| 64 | GG/Saponin | Cartilage regeneration | [ |
| 65 | GG/Chondroitin sulfate | Cartilage regeneration | [ |
| 66 | GG/ Gelatin | Cartilage regeneration | [ |
| 67 | GG/Hesperidin | Cartilage regeneration | [ |
| 68 | GG/ duck feet derived collagen | Tissue Engineering | [ |
| 69 | GG hydrogel | Intervertebral disc | [ |
| 70 | GG/ polyvinyl alcohol | Skin tissue regeneration | [ |
| 71 | GG/PVA/Water | Skin tissue regeneration | [ |
| 72 | GG/Chitosan/ resveratrol | Gastrointestinal delivery | [ |
| 73 | GG/apigenin | Oral drug delivery | [ |
| 74 | GG/Laponite Beads | Gastrointestinal drug release | [ |
| 75 | Maleate GG/Sericin-chitosan |
| [ |
| 76 | GG/sodium alginate/low-methoxyl pectin coated carboxymethyl pullulan-ZnO nanocomposites encapsulating erlotinib | Lung cancer therapy | [ |
| 77 | GG/Triamcinolone acetonide | Topical Ocular Delivery | [ |
| 78 | GG/Sericin/rice bran albumin | Cancer drug delivery | [ |
| 79 | GG/natamycin bilosomes | Ocular pharmacotherapy | [ |
| 80 | GG/Methotrexate | Drug delivery | [ |
| 81 | GG/brinzolamide | Ocular delivery | [ |
Figure 3SEM observation of hydrogel morphology, and 14 days of culturing chondrocyte cells on the scaffold surface [35].
Figure 4MTT assay (a) (values are mean ± SD, n = 3, p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***)), and live (green) and dead (red) images of cells encapsulated in hydrogel analyzed in z-stack mode (b) (scale bar = 100 μm) [35].
Figure 5Scanning electron microscopic (SEM) images showing the cell adhesion and distribution on the surface of prepared hydrogels at 3, 7 and 14 days of culturing. G-gellan gum, P-poloxamer-heparin. The magnified images show the cells adhered to the hydrogel [65].
Figure 6(a) Viability of human Retinal pigment epithelium (ARPE) live and dead cell staining images using a confocal Z-stack (100 μm), on PEG/GG hydrogels on days 1 and 14. Live and dead cells were stained in green and red, respectively. (b) SEM images showing the cell adhesion and proliferation on the surface of the hydrogels (PEG/GG) on days 1 and 7 [37].
Figure 7(a) Proliferation of ARPE at days 1, 3, 5, 7 and 14, studied by MTT assay (n = 3 in each group, p* < 0.5, p** <0.05, and p*** < 0.01). Gene expression of ARPE on PEG/GG hydrogels was analyzed by RT-PCR after 1, 4 and 7 days. (b) Quantitative analysis of retinal pigment epithelial 65 (RPE65) expression (c), Quantitative analysis of NPRA (d), Quantitative analysis of CRALBP normalized to Beta-actin (p* < 0.5, p** < 0.05, and p*** < 0.001) [37].
Figure 8(a) Micro-CT images after in vivo implanted for 2 and 4 weeks, samples of blank, and 2% GG and 1% Gallus gallus var domesticus (GD) demineralized bone powder (DBP) 2% GG samples. (b) Bone mineral density (BMD), (c) Bone surface (BS), (d) Bone volume (BV), (e) Percent bone volume (PBV), (f) Trabecular number (Tb.N), and (g) Trabecular separation (Tb.Sp) (p* < 0.05, p** < 0.01, p*** < 0.001) [36].
Figure 9(a) Pore size of the hydrogels with different agar wt% (p* < 0.05, p** < 0.01, and p*** < 0.001). (b) SEM images of pristine hydrogel and chondrocytes morphology in GG and GG/Agar hydrogel, cultured for 7 and 14 days [39].